Afya Ltd
Afya is a medical education and technology company headquartered in Belo Horizonte, Minas Gerais, Brazil. It supports physicians throughout their professional lifecycle, from medical school and residency preparation through graduate and specialization programs, continuing medical education and clinical practice. Its operations span 21 Brazilian states through undergraduate and graduate campuses, with digital medical platforms available nationwide. Afya operates three segments. Undergraduate provides medical, health science and other degree programs through higher education institutions. Continuing Education offers residency and specialization preparation, graduate courses, medical content and digital learning tools for physicians and medical students. Medical Practice Solutions provides clinical decision support, practice management software, healthcare financial services and digital healthcare tools. Afya earns primarily from monthly tuition fees charged to enrolled students; its technology and professional solutions serve physicians and healthcare providers.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AFYA in the last 30 days.
See all $AFYA insider activity →Afya Limited reported 9M26 revenue of R$2,970M, net income of R$634M, and FCFE of R$629M, with a 45.5% adjusted EBITDA margin. Medical practice users declined 4% YoY, according to the company.
Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results Strong Cash Conversion and Continued Earnings Growth Full-Year 2026 Guidance Reaffirmed Belo Horizonte, Brazil, November 12, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the l
Morgan Stanley upgraded Afya Ltd. (AFYA) to Equalweight, lowering its price target to $12.60. The firm cited Afya's low valuation, robust financials, and limited merger benefits. Afya reported 6% Q2 revenue growth to BRL 972M, with net income up 14%. Other analysts upgraded the stock, citing growth and synergies. The stock trades below Morgan Stanley's target.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning AFYA (Afya Ltd). Coverage has been balanced: 2 bullish, 5 neutral, and 2 bearish.
Recent AFYA coverage spans financial news, earnings and mergers & acquisitions.
Earnings beat on revenue but margin compression and user decline may pressure the stock.
Afya reported solid earnings growth and reaffirmed guidance, supporting a neutral to positive outlook.
The upgrade to Equalweight may provide modest buying support, but the lower price target could cap upside.
Target cut is a mild negative signal, but the retained Overweight rating and still-large implied upside can limit downside.
The upgrade suggests potential upside as analysts become more favorable.
AlphAI scores every news story that mentions AFYA with an AI model for sentiment and relevance, and aggregates insider trades from Afya Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Afya Limited reported 9M26 revenue of R$2,970M, net income of R$634M, and FCFE of R$629M, with a 45.5% adjusted EBITDA margin. Medical practice users declined 4% YoY, according to the company.
Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results Strong Cash Conversion and Continued Earnings Growth Full-Year 2026 Guidance Reaffirmed Belo Horizonte, Brazil, November 12, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the l
Morgan Stanley upgraded Afya Ltd. (AFYA) to Equalweight, lowering its price target to $12.60. The firm cited Afya's low valuation, robust financials, and limited merger benefits. Afya reported 6% Q2 revenue growth to BRL 972M, with net income up 14%. Other analysts upgraded the stock, citing growth and synergies. The stock trades below Morgan Stanley's target.
JP Morgan kept Afya at Overweight but cut its price target to $17.50 from $19, a 7.9% reduction. This implies 64.5% upside from the Nov 2 close of $10.64.
Citigroup upgraded Afya to Buy from Neutral, lowering its price target to $12 from $16, a 25% decrease. The new target implies a 12.8% upside from the Nov 2 close of $10.64.
Bank of America and Barclays recommend two stocks down over 30%: Afya (AFYA), a Brazilian medical education company, and LKQ (LKQ), an automotive parts supplier. Afya's shares dropped due to Brazil's election and a merger announcement, but BofA sees long-term value. LKQ's stock fell due to operational issues in Europe and missed earnings. Barclays is optimistic about LKQ's new CEO and strategic review.
Afya Limited's average price target was reduced from $16.17 to $15.86 by 8 analysts, with a range of $10.56 to $18.82. This implies a 55% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' with 5 Buys, 2 Holds, and 1 Sell.
Analysts made several calls on Wall Street, including Bank of America raising Microsoft's price target to $630, Goldman Sachs reiterating Apple as buy, Morgan Stanley naming Carvana a top pick, and JPMorgan initiating Palantir as overweight. Other notable updates include upgrades for Hilton, Oracle, and Wintrust Financial, while Alphabet was downgraded by Citizens. Analysts also initiated coverage on companies like Rubrik, Fervo Energy, Ormat Technologies, and Absci, with mixed ratings.
BofA upgraded Afya (AFYA) to Buy, lowering its price target to $16. The firm cited Afya's resilient student base, low leverage, and recent exam rule changes as reasons. Afya trades at $10.24, near its 52-week low, with a 6.32 P/E ratio and 30% free cash flow yield. Afya reported 6% Q2 and 7% H1 revenue growth, with net income rising 14% and 7% respectively. JPMorgan also upgraded Afya to Overweight, expecting merger synergies.
Afya (NASDAQ:AFYA) announced a merger with Yduqs, expecting BRL 2.2B in synergies. The companies will operate independently until integration. Afya reported 21% revenue and 22% EBITDA growth from 2021-2026, returning BRL 1.1B to shareholders. The merger could expand Afya's medical education pipeline and improve trading liquidity.
